Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6360958 | 1.00 | NPSR1 (0.40) | NPSR1ALDH1A1L3MBTL1MAPTCYP4F2 | |
| Hydrochloric Acid SCHEMBL6360965 | 0.91 | NPSR1 (0.37) | NPSR1ALDH1A1L3MBTL1MAPTCYP4F2 | |
| SCHEMBL1435555 | 0.74 | NPSR1 (0.47) | NPSR1ALDH1A1L3MBTL1MAPTCYP4F2 | |
| SCHEMBL1434977 | 0.70 | NPSR1 (0.42) | NPSR1ALDH1A1L3MBTL1MAPTCYP4F2 | |
| SCHEMBL1434486 | 0.69 | NPSR1 (0.42) | NPSR1ALDH1A1L3MBTL1MAPTCYP4F2 | |
| SCHEMBL6143483 | 0.67 | NPSR1 (0.46) | NPSR1ALDH1A1L3MBTL1MAPTCYP4F2 | |
| SCHEMBL1604408 | 0.67 | NPSR1 (0.48) | NPSR1ALDH1A1L3MBTL1MAPTCYP4F2 | |
| SCHEMBL20740435 | 0.67 | NPSR1 (0.48) | NPSR1ALDH1A1L3MBTL1MAPTCYP4F2 | |
| Hydrochloric Acid SCHEMBL21296019 | 0.67 | NPSR1 (0.34) | NPSR1LMNA | |
| Hydrochloric Acid SCHEMBL2237016 | 0.67 | NPSR1 (0.34) | NPSR1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | claimed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | claimed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | claimed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | claimed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | claimed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | claimed |
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | disclosed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | disclosed |
| US-6489352-B2 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | disclosed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, GABRA6, GABRA2 | NPSR1 36/4885ALDH1A1 976/4885L3MBTL1 3889/4885 |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | NPSR1 39/4885ALDH1A1 390/4885L3MBTL1 3119/4885 |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | NPSR1 39/4885ALDH1A1 390/4885L3MBTL1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.